Trial · NCT04283669
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NCT04283669, Phase 2, Completed, University of Alabama at Birmingham; results first posted 2026-03-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas. Trials, record NCT04283669. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04283669
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
- NCT number
- NCT04283669
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS)
- Interventions
- Crizotinib
- First posted
- 2020-02-25
- Last updated
- 2026-03-13
- Results first posted
- 2026-03-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Volumetric Response Rate | Up to 48 Weeks | To evaluate efficacy, imaging response is treated as a binary variable whereby patients who achieve a volumetric response (greater than 20% reduction in tumor volume) in the target tumor at any point within 12 months from beginning of therapy are considered responders and all other patients are nonresponders. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Volumetric Response Rate | Up to 48 Weeks | Analysis population consists of 9 participants that received the study treatment. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Volumetric Response Rate | Open Label Continuous Treatment | Responders | 0 | Participants | |
| Volumetric Response Rate | Open Label Continuous Treatment | Non-responders | 9 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Open Label Continuous Treatment | 9 | |
| Overall Study | COMPLETED | Open Label Continuous Treatment | 4 | |
| Overall Study | NOT COMPLETED | Open Label Continuous Treatment | 5 |
Source ClinicalTrials.gov
Adverse events43
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Tinnitus | Ear and labyrinth disorders | Open Label Continuous Treatment | 2 | 9 | |
| other | Blurred vision | Eye disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Extraocular muscle paresis | Eye disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Eye Disorders - Other, Astrocytic Retinal Hamartomas | Eye disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Eye Disorders - Other, Shutter Like Effect | Eye disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Eye Disorders - Other, Vision Changes | Eye disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Constipation | Gastrointestinal disorders | Open Label Continuous Treatment | 1 | 9 | |
| other | Diarrhea | Gastrointestinal disorders | Open Label Continuous Treatment | 7 | 9 | |
| other | Dyspepsia | Gastrointestinal disorders | Open Label Continuous Treatment | 3 | 9 |
1 to 10 of 43Source ClinicalTrials.gov
See all 43 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Open Label Continuous Treatment | 0 | 9 |
| Total, other adverse events | Open Label Continuous Treatment | 9 | 9 |
| Total, serious adverse events | Open Label Continuous Treatment | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04283669
GET https://conductscience.org/api/trials/v1/NCT04283669/events?page=2